Chronic Kidney Disease: Testing a Structured Agenda-Setting Tool for Advanced CKD Patients
Official title: Setting the Agenda: An Open Pilot of a Structured Clinical Visit Agenda-Setting Intervention for Rural-Residing People With Advanced Chronic Kidney Disease
Run by Dartmouth-Hitchcock Medical Center · NCT07221604 · Data updated 2026-11-12
We’re testing a simple, structured discussion tool called CKD Topics with adults with advanced CKD (stages 4–5) to see how well it works before a larger study.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Dartmouth-Hitchcock Medical Center Academic / other |
| Locations | 2 sites (Keene, New Hampshire and 1 other locations) |
| Status | Recruiting |
| Started | May 19, 2026 |
| Main results expected | August 2026 |
| Study ends | September 2026 |
| Registry record updated | July 23, 2026 |
| Trial ID | NCT07221604 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with advanced CKD (stages 4–5), English-speaking, able to consent, and attending outpatient visits (in-person or via telehealth).
✕Probably not a fit
Patients who are non-English-speaking, under 18, on dialysis, or unable to consent may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This open pilot study will use a structured agenda-setting tool (CKD Topics) to guide conversations and collect survey responses from adults with advanced CKD. The goal is to determine whether screening for eligibility, delivering the CKD Topics intervention, and administering surveys can be done smoothly in a real-world setting, especially for patients in rural areas. All participants are in a single-arm feasibility context, aimed at informing a larger stepped-wedge feasibility trial. Findings will help refine procedures for future work. Outcomes focus on process measures and participant feedback rather than clinical efficacy.
Why it matters
Potential benefit: If successful, the approach could improve patient engagement and the planning of care conversations for advanced CKD.
How similar studies have gone: Past work in agenda-setting and patient engagement in CKD is limited; this open pilot explores feasibility rather than proven efficacy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults \>18 years old who have been diagnosed with advanced CKD (stages 4-5). * Care partners, clinicians and staff supporting these CKD patients who are willing and able to provide informed consent * English-speaking * Able to provide informed consent * Patient must be attending outpatient visits \*(in-person and/or telehealth allowable). Exclusion Criteria: * Children under 18 years old will not be included * Non-English-speaking patients and/or care partners * Patients on dialysis * Individuals unable or unwilling to provide informed consent
Where it's running
-
Cheshire Medical Center/Dartmouth-Hitchcock
Keene, New Hampshire, United States Recruiting -
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States Not yet recruiting
Study contacts
- Study coordinator: Catherine H. Saunders, Assistant Professor of Medicine and of Health Policy, PhD, MPH
- Email: Catherine.Hylas.Saunders@dartmouth.edu
- Phone: 603-653-3436
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Home-based exercise to boost fitness for people waiting for a kidney transplant
This study tests whether a 12-week, home-based exercise program plus a wearable activity tracker helps adults on the kidney transplant waiting list increase daily activity and improve physical function.
-
Improving decision-making for older adults with advanced kidney disease
This study is testing a new way to help older adults with advanced kidney disease make better decisions about their treatment by improving communication with their doctors.
-
BZLF1 peptide vaccine with QS-21 to prevent EBV-related cancers in patients awaiting organ transplants
This early-phase trial tests a BZLF1-based vaccine (OSU-2131) with QS-21 to see if it is safe and can help prevent EBV infection and related cancers in healthy people and in patients waiting for a solid organ transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.